-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $4.5

Benzinga·10/13/2026 16:04:53
Listen to the news
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the price target from $4 to $4.5.